AA
VRDN icon

AlphaCentric Advisors’s Viridian Therapeutics VRDN Stock Holding History

AlphaCentric Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$341K – 285
2024
Q3 		$341K Buy
15,000
+2,500
+20% +$40.9K 0.25% 102
2024
Q2 		$163K Buy
12,500
+6,500
+108% +$90K 0.12% 137
2024
Q1 		$105K Buy
+6,000
New +$116K 0.06% 186
2023
Q4 		– Sell
-80,000
Closed -$1.23M – 286
2023
Q3 		$1.23M Buy
80,000
+44,500
+125% +$849K 0.7% 47
2023
Q2 		$845K Hold
35,500
– – 0.47% 75
2023
Q1 		$903K Hold
35,500
– – 0.62% 58
2022
Q4 		$1.04M Hold
35,500
– – 1.02% 34
2022
Q3 		$728K Buy
+35,500
New +$638K 0.75% 45

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return